Kornimate/medical-research-clean huggingface dataset:
postoperative analgesis for pain management after thoracotomy

Conditions: Postoperative Pain; Analgesia

Summary: thoracotomy is among the most painful surgical procedures and can cause severe pain. postoperative pain causes many complications. therefore, pain management is important in patients undergoing thoracotomy. for this purpose, systemic analgesics are used along with ultrasound-guided nerve blocks in thoracotomy pain. the effectiveness of thoracic paravertebral block and serratus plane block in the treatment of post-thoracotomy pain will be evaluated by comparing their effectiveness and complications on postoperative pain. since the epidural spread of the thoracic paravertebral block is more effective, the effectiveness of postoperative pain relief will be more effective

thoracotomy is among the most painful surgical procedures and can cause severe pain. this pain causes postoperative complications in patients who have thoracotomy surgery. uncontrolled pain can cause respiratory and thromboembolic events. therefore, effective pain management is important in patients undergoing thoracotomy. investigators aim to compare the analgesic effectiveness and complications of thoracic paravertebral block and serratus anterior plane block in relieving thoracotomy pain, which is one of the most painful surgical procedures. it is aimed to compare the effectiveness and complications of thoracic paravertebral block and serratus plane block in postoperative pain control after thoracotomy. providing pain control reduces postoperative complications and reduces hospital stay, which increases patient comfort and reduces costs. in this research, postoperative morphine consumption after block applications will be compared, and patients' analgesic needs will be evaluated according to the participants' vas score. post-operative 3rd, 6th, 9th, 12th, 24th. morphine consumption will be evaluated by monitoring the hours. it will be evaluated whether there is a need for additional analgesics. during the operation, the patient's heart rate, blood pressure, saturation and temperature variable values will be closely monitored. standard monitoring methods will be used when examining these parameters.

Eligibility criteria:
inclusion criteria: * 18-75 aged patients * american society of anesthesiologists classification (asa) i-ii-iii patients * patients who scheduled elective thoracic surgery exclusion criteria: * american society of anesthesiologists classification (asa) iv-v patients * patients with coagulopathy * patient with infection at the injection site

Keywords: regional anesthesia paravertebral block serratus plane block thoracotomy
different methods to minimize blood loss during laparoscopic myomectomy; a randomized controlled clinical trial

Conditions: Different Methods to Minimize Blood Loss During Laparoscopic Myomectomy

Summary: laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine will be important to reduce intraoperative bleeding, time of operation and hospitalization period after laparoscopic myomectomy.

laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine will be important to reduce intraoperative bleeding, time of operation, and hospitalization period after laparoscopic myomectomy. this will be the first study to investigate the efficacy of laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine in minimizing blood loss during laparoscopic myomectomy at our university. can laparoscopic myomectomy with temporary bilateral uterine artery occlusion or intramyometrial injection of diluted epinephrine give better outcomes regarding intraoperative bleeding when compared to traditional laparoscopic myomectomy?

Eligibility criteria:
inclusion criteria: 1. women aged from 18 to 39 years. 2. symptomatizing women (heavy menstrual bleeding or subfertility). 3. figo stage (3-7) by ultrasound. 4. only uterine corpus fibroid. 5. up to three fibroids by ultrasound. 6. no previous hormonal treatment. exclusion criteria: 1. patients with bleeding tendency. 2. patients who refuse to participate in the study or uncooperative patients. 3. current pregnancy. 4. any retroperitoneal surgery at pararectal space. 5. more than one cesarean delivery.
intranasal mometasone in children with obstructive sleep apnea due to adenotonsillar hypertrophy

Conditions: Obstructive Sleep Apnea (Mild, Moderate, Severe) as Per Polysomnography

Summary: obstructive sleep apnea (osa) in children is a disorder of breathing during sleep characterized by prolonged partial upper airway obstruction and/or intermittent complete obstruction (obstructive apnea) that disrupts normal breathing during sleep1. the condition occurs in 2-5% of children and can occur at any age, but it is most common in children between the ages of 2 to 62,3. untreated osa is associated with lung disease, heart disease, growth delay, poor learning and behavioral problems such as inattention and hyperactivity. the most common underlying risk factor for the development of osa is enlargement of tonsils and adenoids. given the potential risk of complications associated with surgery of the tonsils and adenoids, medications to shrink the adenoids without requiring surgery have been considered, in particular intranasal corticosteroids (incss) which is a nose spray. a recent cochrane systematic review suggested a short-term benefit of incss in children with mild to moderate osa4. the authors recommended that further randomised controlled studies were required to evaluate the efficacy of incss in children with osa. in particular they recommended that future studies should employ sleep studies to look for any improvement with incss, and should include children with more severe osa, as these are the patients at the greatest risk of complications of surgery and would benefit most from a non-surgical treatment. the purpose of this study is therefore to explore the efficacy of incss in children with the full spectrum of osa severity, including sleep study analysis., and longer term follow-up.


Eligibility criteria:
inclusion criteria: * children between age 3 and 16 with objectively diagnosed osa (mild, moderate, severe) as per polysomnography (ahi ≥ 1/h, where ahi is the sum of obstructive and mixed apneas and obstructive hypopneas). exclusion criteria: * children with malformation syndromes or craniofacial anomalies * children with neuromuscular disorders * children with morbid obesity (body mass index ≥ 40) * children with asthma requiring steroid treatment
nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer

Conditions: Breast Carcinoma; Cholangiocarcinoma; Colorectal Carcinoma; Gastric Carcinoma; Malignant Digestive System Neoplasm; Pancreatic Carcinoma; Prostate Carcinoma

Summary: this trial studies nutritional preferences and product accessibility in oral nutritional supplements in participants with breast, colorectal, upper gastrointestinal, or prostate cancer. learning what participants like and dislike about their current or past used nutritional supplements may help doctor know how to improve them.

primary objectives: i. identify how patients with cancer are obtaining nutrition to support medical management. secondary objectives: i. examine associations of gastrointestinal side effects with specific diagnoses and respective medical therapies. ii. understand how patients access information regarding nutritional supplements. iii. evaluate patient satisfaction with currently available oral nutritional supplements (ons). iv. identify patient preferences in formulating a novel nutritional supplement. outline: participants attend an interview over 15 minutes and complete surveys.

Eligibility criteria:
inclusion criteria: * ability to comprehend english (both reading and writing) * subjects in the inpatient and outpatient setting with the diagnosis of breast cancer, colorectal cancer, upper gastrointestinal cancer (including gastric, pancreatic, and cholangiocarcinoma), or prostate cancer * receiving chemotherapy, biologic, or hormonal therapy in the university of southern california (usc) norris comprehensive cancer center day hospital * ability to understand and the willingness to sign a written informed consent exclusion criteria: * patients with a mental disability that makes them unable to understand and respond to the questions * patients with reported non-oncologic associated deficits in taste and smell
treating wheezing in children with hypertonic saline (twics)

Conditions: Wheeze

Summary: hypothesis: substitution of nebulized 3% nacl (hs) for the standard normal saline (ns) used in bronchodilator therapy for acute viral wheezing in all children under age 6 years will provide superior symptom relief leading to decreased admission rates from the emergency department. the study will test the efficacy of frequent doses of inhaled bronchodilator co-administered with either 3% hypertonic saline (hs, study group) or 0.9% normal saline (ns, control group) in a prospective, double blind, randomized controlled, multi-centre clinical trial of children under age 6 years presenting to the ed with acute viral-associated wheezing.

the brief summary captures the essence of the study

Eligibility criteria:
inclusion criteria: 1. age under 6 years 2. history of viral upper respiratory infection within previous 7 days 3. wheezing or crackles detected on chest auscultation 4. respiratory distress assessment instrument (rdai) score of 4 or greater or oxygen saturation (sao2) of 94% or less in room air. exclusion criteria: 1. history of immunodeficiency, chronic cardiopulmonary disease (other than past history of wheezing), down syndrome, gestational age under 34 weeks. 2. severe illness at presentation as defined by any of the following * respiratory rate greater than 80/min * sao2 less than 88% in room air * need for assisted ventilation 3. use of nebulized hs within previous 12 hours 4. presence of active varicella infection.

Keywords: wheeze early childhood asthma bronchiolitis infection triggered
optimization of atopic dermatitis treatment that requires second-line systemic therapy through predictive models

Conditions: Atopic Dermatitis

Summary: this is a low-intervention phase iv trial. the main objective is to optimize the treatment of patients with moderate-severe atopic dermatitis that require systemic treatment after failure, intolerance or contraindication to cyclosporine.

primary outcome is the percentage of patients with primary non-response to second-line treatment. defined as fail to achieve easi-75 (a 75% improvement in easi score) at week 16 of follow-up. a 12-month recruitment period is planned and about 150 patients with moderate-severe atopic dermatitis will be recruited. the study is divided into two cohorts. all patients diagnosed with moderate to severe atopic dermatitis who are going to receive second-line systemic treatment at the dermatology department of la paz university hospital are selected in cohort 1. patients will receive the starting dose used in routine clinical practice. all patients diagnosed with moderate to severe atopic dermatitis who are receiving second-line systemic treatment at the dermatology department of la paz university hospital will be selected in cohort 2.

Eligibility criteria:
inclusion criteria: cohort 1: 1. subjects diagnosed with moderate-severe atopic dermatitis who are going to receive an authorized second-line systemic treatment. 2. participants must be willing and able to provide written informed consent prior the initiation of any study procedures. 3. for children, parent/legal guardian must provide written informed consent. if age \>11 years old, the minor must give assent. 4. participant is willing and able to adhere to the procedures specified in this protocol. cohort 2: 1. subjects diagnosed with moderate-severe atopic dermatitis who are already receiving authorized second-line systemic therapy at the time of selection. 2. participants must be willing and able to provide written informed consent prior the initiation of any study procedures. 3. for children, parent/legal guardian must provide written informed consent. if age \>11 years old, the minor must give assent. 4. participant is willing and able to adhere to the procedures specified in this protocol. exclusion criteria: 1. any investigational drug within 60 days prior to study drug administration. 2. any condition or situation precluding or interfering the compliance with the protocol. 3. women of childbearing potential must have a negative urine pregnancy test at screening and day 0. 4. women of childbearing potential must commit not to become pregnant. they must be willing to use highly effective contraceptive methods or have practiced sexual abstinence during the study. highly effective contraceptive methods include oral, intravaginal, or transdermal combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation; oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation; intrauterine device; intrauterine hormone-releasing system; bilateral tubal occlusion; vasectomised partner and sexual abstinence.
biologically focused therapy of treatment-refractory mds patients

Conditions: Myelodysplastic Syndromes

Summary: this non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

this study utilizes the notable labs personalized testing service using an ex vivo assay, but does not involve actual treatment or treatment determinations. the results of these screenings will be made available to patients and their physicians for their use off study. the primary objective of the study is: • to determine the feasibility of selecting patient specific treatment regimens based on ex vivo within 30 days the exploratory objectives of the study are: • to identify biomarkers that explain ex vivo drug sensitivity results

Eligibility criteria:
inclusion criteria: * provide informed consent; * myelodysplastic syndrome as defined by who classification (see appendix 2), or mds/mpn with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (cmml) 1 and 2 by who classification * relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy * cytogenetics reported exclusion criteria: * hypoplastic mds * patients without adequate marrow samples for ex vivo analysis

Keywords: mds
safety and efficacy study of zilucoplan in subjects with immune-mediated necrotizing myopathy

Conditions: Immune Mediated Necrotizing Myopathy

Summary: the purpose of the study is to evaluate the safety and efficacy of zilucoplan in patients with immune-mediated necrotizing myopathy (imnm). subjects will be randomized in a 1:1 ratio to receive daily sc doses of 0.3 mg/kg zilucoplan or matching placebo for 8 weeks.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of imnm (immune-mediated necrotizing myopathy) * positive serology for anti-3-hydroxy-3-methyl-glutaryl-coenzyme a reductase (hmgcr) or anti-signal recognition particle (srp) autoantibodies * clinical evidence of weakness (≤ grade 4 out of 5) on manual muscle testing in at least one proximal limb muscle group * creatine kinase (ck) of \>1000 u/l at screening * no change in corticosteroid dose for at least 30 days prior to baseline or anticipated to occur during the first 8-weeks on study * no changes in immunosuppressive therapy, including dose, for at least 30 days prior to baseline or anticipated to occur during the first 8-weeks on study exclusion criteria: * history of meningococcal disease * current or recent systemic infection within 2 weeks prior to screening or infection requiring intravenous (iv) antibiotics within 4 weeks prior to screening * recent initiation of intravenous immunoglobulin (ivig) (i.e., first cycle administered less than 90 days prior to baseline) * rituximab use within 90 days prior to baseline or anticipated to occur during study * statin use within 30 days prior to baseline or anticipated to occur during study * plasma exchange within 4 weeks prior to baseline or expected to occur during the 8-week treatment period
cardiometabolic risk, obesity and cardiovascular disease in people with spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of this study is to develop and field-test new tools for diagnosis and hazard assessment of cardiometabolic risk (cmr) in people with chronic spinal cord injury (sci) and to advance the evidence base with much needed information on cmr and cardiovascular disease (cvd) burden in people with sci. these data can be used to develop screening guidelines for early identification and prevention of cmr in sci, as well as targeted approaches to primary disease management.

unlike current assessments utilizing lipid scores, the new system will be anchored in more reliable measurements of cardiovascular disease (cvd) burden using contemporary surrogate end points of coronary artery calcium (cac) score, coronary ct angiography and carotid intima media thickness (cimt). by the end of the 5-year funding cycle we will develop an updatable web-based cardiometabolic risk assessment tool (risk) that will allow clinicians and sci consumers to quantify risk for a cardiovascular sentinel event (stroke, non-fatal heart attack, or death) and will also provide a body mass index (bmi) table adjusted for sci. specific aims: 1. examine the relationships among surrogates of cardiovascular disease burden in persons with sci and established cardiometabolic risks. 2. identify significant predictors of cardiometabolic risk (cmr) that are unique to persons with specific levels of sci. 3. develop and validate sci cmr assessment tool (risk) based on cardiometabolic risk scores. 4. develop and validate an adjusted bmi table for sci.

Eligibility criteria:
inclusion criteria: * traumatic spinal cord injury between c4 and t12 * have a motor complete injury as classified as american spinal injury association impairment scale (ais) grade a or b * injury for more than 1 year * no known history of traumatic brain injury, cardiovascular disease or diabetes * not currently taking any medications to treat cardiovascular disease or diabetes * have multiple (i.e., 2+) of the following cardiometabolic risk factors: 1. fasting triglyceride \> 150 mg/dl 2. hdlc \< 40 mg/dl 3. hs-crp \> 3.0 4. body fat (by dexa) \>25% for males and 33% for females exclusion criteria: * history of allergy or hypersensitivity to fish and/or nuts * undergoing anticoagulant therapies
peking university birth cohort in weifang (pkubc-wf)

Conditions: Health Problems in Pregnancy; Pregnancy Outcomes; Gestational Diabetes; Gestational Hypertension; Preterm Birth; Obesity; Mother-Infant Interaction; Child Development; Anemia

Summary: the pkubc-wf is a prospective cohort study carried out in weifang city of shandong, china. the primary aim of this study is to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers and their children from birth to before 18 years old. biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces are also collected.

maternal and child health is of great concern globally. early life phase of a fetus and infant is a critical period for the development of health and disease in the whole life. exposure of negative environmental, nutritional and lifestyle factors in pregnant women during this period can have adverse effects on fetal and infant. in addition, for mothers, complications during pregnancy could also have a negative effect on long-term health of mothers, such as diabetes, hypertension. thus, the peking university birth cohort in weifang is primarily aimed to investigate the short-term and long-term effects of pre-pregnant and prenatal exposure on maternal and child health. data are collected regarding environmental, nutritional and lifestyle exposures as well as short-term and long-term health outcomes of mothers, husbands and their children from birth to before 18 years old. biological samples including peripheral blood, urine, placenta, umbilical cord, cord blood, and faeces samples are also collected.

Eligibility criteria:
inclusion criteria: * pregnant woman 1. pregnant women, 6-13\^+6 gestational weeks 2. resided in weifang in the past half years and have no plan to move out after delivery 3. pregnant women who plan to have antenatal care and delivery in weifang maternal\&child hospital. 4. pregnant women who is willing to participate in this study with informed consent * pregnant woman's husband 1. his wife was eligible for enrollment 2. he is the biological father of the child (his wife's current pregnancy) 3. pregnant women's husband who is willing to participate in this study with informed consent * offspring 4. children born to pregnant women who met the inclusion criteria after enrolling in this study. 5. before the age of 8 years, his/her mother provided written informed consent. 6. after 8 years old, he/she agreed to continue this study and signed the informed consent. exclusion criteria: * participants who cannot communicate normally.